News & Events
Press releases, clinical milestones, and conference appearances from Eloxx Pharmaceuticals.
Recent announcements
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of $66.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Eloxx. The shares of common stock are expected to begin trading on the Nasdaq Capital Market on June 9, 2026, under the symbol "ELOX". The offering is expected to close on June 10, 2026, subject to the satisfaction of customary closing conditions.
Read press release →Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Data from Eloxx's proof-of-concept trial in NMAS patients presented in a late-breaking presentation at ASN Kidney Week. New protein analyses confirm production of both collagen α4 and collagen α5 in patients post-treatment with ELX-02. FDA allows continued dosing of subjects in Phase 1 trial of ZKN-013.
Read press release →Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013. Positive written FDA feedback from pre-IND meeting provides pathway to IND submission for a US Phase 2 trial of ELX-02 in NMAS patients. Eloxx secures $3.2 million in additional financing to advance clinical programs.
Read press release →Almirall and Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for rare dermatological diseases including RDEB and JEB caused by nonsense mutations. Eloxx receives $3 million upfront and is eligible for up to $470 million in milestones plus tiered royalties on global sales.
Read press release →Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy-confirmed disease regression. Post-treatment UPCR rebound in one patient confirms on-treatment remission was drug-related. IND application submitted to US FDA for ELX-02 in nonsense mutation Alport syndrome.
Read press release →Exaluren Induces COL4A5 Readthrough Across 49 Nonsense Variants in Alport Syndrome
Omachi et al. published in iScience a systematic screen of exaluren across 49 COL4A5 nonsense variants, demonstrating readthrough activity across all variants tested, with some mutations showing greater than 40-fold enhancement. These data underpin the scientific rationale for the NMAS program.
Read publication →Upcoming appearances
Eloxx scientists and management present at major nephrology and rare disease conferences.
No upcoming events. Add one in the WordPress admin under Events & Conferences → Add New.
Contact our investor relations team
For press enquiries, investor information requests, or to be added to our media list, contact:
ir@eloxxpharma.com SEC Filings →